4/A: Rocket Pharmaceuticals Director Gotham Makker Amends Filing to Correctly Report Beneficial Ownership

Gotham Makker, a director of Rocket Pharmaceuticals, amended a previous SEC Form 4 filing to accurately reflect beneficial ownership of common stock, including shares held by a non-revocable trust.

Summary

• Gotham Makker, a director of Rocket Pharmaceuticals, filed an amended SEC Form 4 to correct an error in a previous filing.
• The amendment concerns the reporting of beneficial ownership of Rocket Pharmaceuticals' common stock.
• The original filing on March 25, 2024, omitted shares held by a non-revocable trust for the benefit of Makker's children.
• The corrected filing shows that Makker directly owns 365,912 shares and indirectly owns 621,500 shares through a non-revocable trust and 274,000 shares through Simran Investment Group.
• Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein.
• On March 21, 2024, Simran Investment Group disposed of 274,000 shares at a price of $28.4341.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to insider trading and beneficial ownership, which is a standard practice for publicly traded companies like Rocket Pharmaceuticals. It ensures transparency and compliance with SEC regulations.

Key Dates